Intellipharmaceutics International Inc. Quarterly Additional Paid in Capital in USD from Q4 2010 to Q3 2023

Taxonomy & unit
us-gaap: CAD and USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
Intellipharmaceutics International Inc. quarterly Additional Paid in Capital history and growth rate from Q4 2010 to Q3 2023.
  • Intellipharmaceutics International Inc. Additional Paid in Capital for the quarter ending August 31, 2023 was $45.1M, a 1.01% increase year-over-year.
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2023 $45.1M +$450K +1.01% Aug 31, 2023 6-K 2023-10-16
Q2 2023 $45.1M +$450K +1.01% May 31, 2023 6-K 2023-09-26
Q1 2023 $45.1M +$450K +1.01% Feb 28, 2023 6-K 2023-09-26
Q4 2022 $45.1M +$471K +1.06% Nov 30, 2022 20-F/A 2024-02-06
Q3 2022 $44.6M -$10.5K -0.02% Aug 31, 2022 6-K 2022-10-14
Q2 2022 $44.6M +$114K +0.26% May 31, 2022 6-K 2022-07-21
Q1 2022 $44.6M +$241K +0.54% Feb 28, 2022 6-K 2022-04-14
Q4 2021 $44.6M +$272K +0.61% Nov 30, 2021 20-F/A 2024-02-06
Q3 2021 $44.7M +$296K +0.67% Aug 31, 2021 6-K 2021-10-15
Q2 2021 $44.5M +$268K +0.61% May 31, 2021 6-K 2021-07-15
Q1 2021 $44.4M +$216K +0.49% Feb 28, 2021 6-K 2021-04-14
Q4 2020 $44.4M +$186K +0.42% Nov 30, 2020 20-F/A 2022-05-09
Q3 2020 $44.4M +$242K +0.55% Aug 31, 2020 6-K 2020-10-15
Q2 2020 $44.3M -$28.3K -0.06% May 31, 2020 6-K 2020-07-15
Q1 2020 $44.2M +$4.36K +0.01% Feb 29, 2020 6-K 2020-05-29
Q4 2019 $44.2M -$943K -2.09% Nov 30, 2019 20-F 2021-03-31
Q3 2019 $44.1M +$6.22M +16.4% Aug 31, 2019 6-K 2019-10-11
Q2 2019 $44.3M +$6.42M +17% May 31, 2019 6-K 2019-07-10
Q1 2019 $44.2M Feb 28, 2019 6-K 2019-04-15
Q4 2018 $45.1M +$8.43M +23% Nov 30, 2018 20-F 2020-03-30
Q3 2018 $37.9M Aug 31, 2018 6-K 2018-10-15
Q2 2018 $37.9M May 31, 2018 6-K/A 2018-07-24
Q4 2017 $36.7M Nov 30, 2017 6-K 2018-10-15
Q4 2015 $31M -$151K -0.49% Nov 30, 2015 20-F 2016-03-21
Q4 2014 $31.1M +$7.5M +31.8% Nov 30, 2014 20-F 2016-03-21
Q1 2014 $29.7M Feb 28, 2014 6-K 2014-04-14
Q4 2013 $23.6M +$1.19M +5.31% Nov 30, 2013 20-F 2015-02-27
Q4 2012 $22.4M +$1.61M +7.71% Nov 30, 2012 20-F 2014-02-18
Q4 2011 $20.8M +$1.45M +7.51% Nov 30, 2011 20-F/A 2013-02-01
Q4 2010 $19.4M Nov 30, 2010 20-F 2012-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.